NPS+(미국) : 신세포암(RCC)

This report examines the competitive landscape of US Renal Cell Carcinoma therapies, drawing on insights from 100 US oncologists. Using the NPS+ framework, it provides a detailed view of brand health by comparing Net Promoter Scores across key therapies and analyzing the underlying drivers of physician satisfaction and loyalty. The report explores how brand perceptions differ between Promoters and Detractors, the messages most associated with leading brands, and the prescribing value of loyal physicians. It also identifies switching risks and reveals how each brand is positioned relative to its competitors, offering a clear view of current market dynamics and future threats to brand share.

Key Questions Answered:

• 1. How do NPS scores by brand compare?
• 2. How loyal are physicians to specific brands?
• 3. What brand messages resonate with physicians?
• 4. What are the key factors driving physician choice?
• 5. What is the market share of leading brands?
• 6. How does each of the leading brands compare to its competitors?
• 7. Which brands are vulnerable to switching due to low brand satisfaction?

Key Brands:

Methodology:

FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.